tbuckley/cabot-search huggingface dataset:
NUEVO MÉTODO PARA EL DIAGNÓSTICO HISTOLÓGICO DE LESIONES QUÍSTICAS PANCREÁTICAS MEDIANTE ECOENDOSCOPIA (USE)
Authors: JR Aparicio, J Martínez, M Niveiro, A Cabezas, F Ruiz, JA Casellas
Journal: Endoscopy (2010)

El rendimiento de la USE-PAAF es bajo en los quistes de páncreas. La posibilidad de obtener biopsias de la pared podría mejorar estos resultados. Presentamos la primera experiencia en el diagnóstico de 2 pacientes con quiste de páncreas mediante biopsia intraquística a través de una aguja de punción guiada por USE.
AB0752 Ultrasound features of shoulder involvement in patients with ankylosing spondylitis: a case-control study
Authors: S. Ali Ou Alla, R. Bahiri, H. Amine, H. El Alaoui, H. Rkain, S. Aktaou, R. Abouqal, N. Hajjaj-Hassouni
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> to investigate the prevalence of ultrasound (US) abnormalities in shoulders of patients with ankylosing spondylitis (AS), and to determine predictive factors of ultrasound shoulder enthesitis. <h3>Methods</h3> 38 AS patients were included with 38 age and sex-matched healthy controls. All patients fulfilled the modified New York criteria for ankylosing spondylitis. Clinical and demographical data were recorded. US examination of bilateral shoulders was performed by a musculoskeletal sonographer according to a defined protocol that included imaging of the insertions of supraspinatus, subscapularis and infraspinatus tendons, rotator cuff tendons, subacromial-subdeltoid bursa, acromioclavicular joint, and glenohumeral joint. <h3>Results</h3> the mean age of patients and controls was 36 years, each group of patients and controls comprised 22 men (57.9%) and 16 women (42.1%). Disease duration was 9.6±7.2 years. Among 38 AS patients, 21 had coxitis (55%) and 19 had previous or current shoulder pain (50%). AS shoulders presented significantly more ultrasound enthesitis than controls shoulders (43 shoulders (56.6%) versus 8 shoulders (10.5%) respectively). Involvement of rotator cuff tendons was significantly higher in AS patients compared with control subjects (16/38 (42.1%) versus 6 (15.2%) respectively). However, involvement of glenohumeral and acromioclavicular joints was infrequent in both groups. In AS patients, we found that the presence of coxitis was the only significant predictive factors of shoulder enthesitis (Odds Ratio (OR) =9.4; Confidence interval (CI)95% (1.10; 81.9), p=0.04) <h3>Conclusions</h3> Ultrasound abnormalities of shoulders are common in patients with ankylosing spondylitis, and the most frequent abnormality was enthesitis, which was associated with the presence of coxitis. <h3>Disclosure of Interest</h3> None Declared
Intense Accumulation of Tc-99m Tetrofosmin in Chronic Pneumonia
Authors: EIJI OHTAKE, TSUTOMU FUKUDA, HIDEYUKI HASEGAWA, YASUHIRO KIDO
Journal: Clinical Nuclear Medicine (1997)

A 56-year old woman was suspected to have lung cancer and was examined by thoracic SPECT using Tc-99m tetrofosmin. Intense uptake was observed in the right lung lesion. A right upper lobectomy was performed, and the diagnosis was chronic pneumonia, which was provided with an organic structure.
AB0456 Combination Leflunomide and Methotreaxate in Refractory RA: A Biologic-Sparing Approach
Authors: K.R. Magomero, B. Hodkinson, M. Tikly
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> In resource-constrained settings where biologic agents are not widely available, there are limited therapeutic option for patients with rheumatoid arthritis (RA) refractory to triple disease modifying antirheumatic (DMARD) combination therapy <h3>Objectives</h3> To evaluate the efficacy and safety of leflunomide with methotrexate (MTX/LEF) in refractory RA <h3>Methods</h3> A retrospective record review of adult RA patients treated with MTX/LEF for ≥4 months at a tertiary hospital in South Africa between 2007 and 2013. Demographic details, adverse reactions, interruptions in therapy and the 3-variable 28 joint disease activity scores (DAS28-3) score were recorded at initiation of LEF/MTX therapy (DAS28-3B), after 4 and 12 months of treatment and at last visit (DAS28-3L). <h3>Results</h3> In the 194 predominantly middle-aged female patients with established disease (93% female, mean (SD) age 40.1 (12.2) yrs, disease duration of 12.4 (8.2) and time on previous DMARDs of 7.0 (5.5) yrs. The mean (SD) DAS28-3B was 5.3 (1.0). Following initiation of MTX/LEF, 58.6% of patients achieved a good EULAR response at 4 months, improving to 62.3% by 12 months. In the 172 patients who continued therapy to last visit (a mean (SD) of 2.5 (1.6) yrs), the DAS28-3L had improved significantly to a mean (SD) of 3.6 (1.2), p&lt;0.0001, with 93 patients (54.1%) achieving low disease activity or remission. Therapy was discontinued in 22 patients, for reasons including the wish to fall pregnant, human immunodeficiency virus (HIV) seroconversion, and poor adherence to treatment. Therapy was discontinued in a further 17 (8.8%) patients because of toxicity, and hepatotoxicity (n=3), intolerable gastrointestinal symptoms (n=3), and leucopaenia with septicaemia (n=3) were the most common problems. Two patients died while on LEF therapy and 19 (9.8%) patients were lost to follow up. Treatment was interrupted for more than one month in 153 (89.0%) of patients, most commonly due to inadequate pharmacy supplies of LEF. The significant predictors of a Eular good response to MTX/LEF was a DAS28-3B ≤5.5 (OR=5.1 (95% CI 2.7-9.6), p&lt;0001), and uninterrupted therapy (OR=7.5 (95% CI 2.4-23.8, p=0.0002). <h3>Conclusions</h3> The combination of LEF/MTX was effective in the majority of patients who failed other combination synthetic DMARDs, particularly in those with DAS28-B &lt;5.5, and in those without interruptions to this therapy. These results are gratifying despite erratic pharmaceutical supplies of drugs. Fewer than 10% stopped therapy because of adverse effects, and the retention rate was 70%. In a setting where biologic DMARDs are not readily accessible, the combination of LEF/MTX is a cost-effective and relatively safe resource-sparing approach. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5338
PMO-252 Efficacy of infliximab therapy in acute and sub-acute ulcerative colitis
Authors: E Harrison, J Slater, L Wood, S C Cooper, S de Silva
Journal: Gut (2012)

<h3>Introduction</h3> Ulcerative colitis (UC) has a chronic relapsing course. Infliximab is beneficial in severe disease, but conflicting data exists regarding the subsequent colectomy rates. We aimed to review outcomes post-infliximab usage in acute and sub-acute UC in our clinical practice. <h3>Methods</h3> We conducted a retrospective review of all patients who had received a maximum of three doses of infliximab for acute or sub-acute exacerbations of UC between January 2010 and October 2011. Medical treatment (initial and subsequent) and colectomy rates were recorded for all patients. <h3>Results</h3> 21 patients received infliximab during the study period. 12 patients were emergency admissions who had failed to respond to intravenous steroid therapy (acute group). Nine patients had failed to respond to maximum oral therapy, which included immunomodulators and oral prednisolone (sub-acute group). In the acute group, 42% (n=5) of patients had avoided a colectomy at a median follow-up of 467 days (IQR 370–612). The other 58% (n=7) proceeded to colectomy after a median of 69 days (IQR 30–136). Of the patients who proceeded to colectomy, 57% had been prescribed immunomodulator therapy prior to infliximab usage. However, all the patients who avoided colectomy were immunomodulator naive prior to infliximab. In the sub-acute group, only 33% (n=3) of patients required a colectomy after a median follow-up of 153 days (IQR 110–180). The remaining 67% (n=6) were well and off steroids after a median of 303 days (IQR 209–400). <h3>Conclusion</h3> This review of patient outcomes shows the potential benefits of infliximab for treating both acute and sub-acute UC. After a maximum of three doses of infliximab, 42% of acute and 67% of sub-acute UC patients were able to avoid a colectomy. Our results are comparable to those of Oxford (1 to 7 doses of infliximab as needed) who reported that 43% of acute and 50% of sub-acute were able to avoid a colectomy.<sup>1</sup> Furthermore, our results confirm the greater potential benefit of infliximab in acute, immunomodulator naive patients. In addition, all sub-acute patients, who avoided colectomy, were well and off steroids at the end-of follow-up, compared to only 38% from the Oxford group, suggesting additional benefit from planned infliximab doses.<sup>1</sup> <h3>Competing interests</h3> None declared. <h3>Reference</h3> 1. <b>Jakobovits SL</b>, Jewell DP, Travis SPL. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. <i>Aliment Pharmacol Ther</i> 2007;<b>25</b>:1055–60.
Abstract 2210: Activation of PI3K in Merkel cell carcinoma
Authors: Valentina Nardi, Young Chul Song, Arjola K. Cosper, Quynh Lam, Juan Antonio Santamaria Barria, Genevieve Marie Boland, Beow Yeap, Kristin Bergethon, Vanessa L. Scialabba, Jeffrey Settleman, David P. Ryan, Darrell R. Borger, Mai P. Hoang, Atul K. Bhan, Anthony J. Iafrate, James C. Cusack, Jeffrey A. Engelman, Dora Dias-Santagata
Journal: Cancer Research (2011)

Abstract Background: Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous neuroendocrine tumor, often metastatic at presentation, with a median survival time of 6.8 months for stage IV disease. Current chemotherapeutic regimens are largely ineffective. It is still unknown whether established oncogenes or tumor suppressors are major players in the pathogenesis of MCC. Recently, a new polyomavirus has been identified in 50 to 80% of MCC, but a mechanistic role for this virus in the pathogenesis of MCC has not yet been demonstrated. We hypothesized that deregulation of signaling pathways that are commonly activated in cancer may contribute to MCC tumorigenesis and may provide insights into targeted therapy approaches for this malignancy. Design: We retrospectively profiled 60 primary MCC samples diagnosed at the MGH from 1995 to 2010 using a recently developed SNaPshot genotyping assay to screen for the presence of common mutations in 13 cancer genes, many of which are targeted by FDA approved drugs or by targeted agents undergoing clinical trials. In addition, all MCC samples were tested for the presence of Merkel cell polyomavirus (MCPyV) using PCR. Results: The SnaPshot assay identified mutations in 15% (9/60) of MCC primary tumors. The TP53 tumor suppressor gene was mutated in 3 of 60 cases and activating mutations in the p110 alpha subunit of the phosphatidylinositol 3-kinase (PIK3CA) gene were found in 6 of 60 cases. Sanger sequencing of the primary MCC tumors identified one additional PIK3CA mutation (R19K) that has not been previously described in cancer. In primary MCC cell lines, we observed that the presence of a PI3KCA activating mutation was associated with sensitivity to treatment with NVP-BEZ-235, a dual PI3K-mTOR inhibitor currently under active clinical development. Clinical correlations with PIK3CA mutational status and the presence of MCPyV are ongoing. Conclusions: We discovered that a subset of patients with MCC (10%) carry activating mutations in PIK3CA. Furthermore, we found that a MCC cell line harboring a PIK3CA mutation is selectively sensitive to a PI3K inhibitor under clinical development. Our results suggest the relevance of screening patients with MCC for activation of the PI3K pathway, as these cancers may be particularly sensitive to PI3K pathway inhibitors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2210. doi:10.1158/1538-7445.AM2011-2210
AB0267 Does the change of questions assessing patient’s global assessment influence composite scores in rheumatoid arthritis? is there also an influence on agreement of the composite scores to a patient outcome measure like the RADAI-5?
Authors: B. Rintelen, J. Sautner, K. Stingl, N. Kalmann, B.F. Leeb
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> 2011 the ACR and EULAR proposed new remission criteria for Rheumatoid arthritis (RA) [1]. According to this publication from now on wording of the question about patient's global assessment should be as follows: "Considering all of the ways your arthritis has affected you, how do you feel your arthritis is today?" In the past general health was not explicitly connected to arthritis but to the general health condition. <h3>Objectives</h3> It was of interest if the use of the new wording influences the agreement of composite scores to patient centred disease activity assessment tools like for example the Rheumatoid Arthritis Disease Activity Index comprising 5 questions (RADAI-5) which has shown significant correlation to the commonly used composite indices [2,3]. <h3>Methods</h3> 177 consecutive outclinic RA patients (74% female, mean age 63,6 years, 55.9% RF pos, mean disease duration 110 months) were asked to answer both questions ("How is your general health today?" and "Considering all of the ways your arthritis has affected you, how do you feel your arthritis is today?") on a 100 mm visual analogue scale (VAS-old and VAS-new). Moreover DAS28, SDAI and CDAI were calculated twice using both questions. Furthermore patients were asked to complete the RADAI-5 to correlate this questionnaire to the other composite scores. Cohen's kappa was calculated to show the agreement of both results. <h3>Results</h3> The mean RADAI-5 was 3.17 (95%CI 2.85 - 3.49). Agreement of VAS-old and VAS-new was moderate (kappa =0.41). The RADAI-5 agrees better to SDAI and CDAI using VAS-new than VAS-old (kappa =0.68 vs. 0.27 and 0.76 vs. 0.27 respectively). No substantial difference was found for the agreement between RADAI-5 and DAS28 using both wordings (kappa =0.20 vs. 0.26). <h3>Conclusions</h3> VAS-old and VAS-new showed a moderate agreement. No difference in agreement of the DAS28 and the RADAI-5 was seen using both wordings. By introducing the new wording the SDAI and the CDAI become much more congruent with the RADAI-5 and probably other patient related outcomes. <h3>References</h3> Felson DT, Smolen JS, Wells G et al. Ann Rheum Dis. 2011 Mar;70(3):404-132. Leeb BF, Haindl PM, Maktari A et al. J Rheumatol. 2008 Jul;35(7):1294-9. Bossert M, Prati C, Vidal C et al. Joint Bone Spine. 2012 Jan;79(1):57-62. <h3>Disclosure of Interest</h3> None Declared
Ipilimumab-induced colitis: a rare but serious side effect
Authors: Alisha Hinds, Dina Ahmad, Joseph Muenster, Zachary Berg, Kristi Lopez, Jason Holly, Michelle Matteson-Kome, Matthew Bechtold
Journal: Endoscopy (2014)

Colitis is a serious condition with associated morbidity and mortality. Colitis may be caused by multiple agents, including ischemia, infection, irritable bowel disease, and medications. Ipilimumab, a monoclonal antibody used for the treatment of melanoma, has in rare cases been associated with colitis [1]. This case report describes one such rare case of ipilimumab-induced colitis.
PRÓTESIS ESOFÁGICAS PARA EL TRATAMIENTO DE DEHISCENCIAS ANASTOMÓTICAS ESOFAGOGÁSTRICAS (DAEG)
Authors: R Jijón, A Serrano, F Alberca, J Egea, J Álvarez, M Alajarín, A Ono, B García, M Muñoz, G Antón, F Carballo
Journal: Endoscopy (2014)

Introducción: No existe un tratamiento estandarizado para el tratamiento de las DAEG y aún se debate por la preferencia entre tratamiento endoscópico o quirúrgico. En los últimos años, nuevas opciones de tratamiento endoscópico han surgido, como el cierre con grapas o suturas, sellado con pegamento biológico y colocación de endoprótesis. El uso de prótesis esofágicas ha irrumpido como un tratamiento efectivo para las DAEG. Se ha descrito que un periodo de 6 – 8 semanas es seguro y eficaz para su reparación.
Reporter Gene Transfer Induces Apoptosis in Primary Cortical Neurons
Authors: Eric R Detrait, William J Bowers, Marc W Halterman, Rita E Giuliano, Lisa Bennice, Howard J Federoff, Eric K Richfield
Journal: Molecular Therapy (2002)

<h2>Abstract</h2> Modern cell biologists typically use reporter genes either alone or co-expressed with a protein of interest to facilitate the localization or quantification of protein expression. Our work demonstrates that reporter genes should be used cautiously, as several common reporter gene products are toxic to primary cortical neuronal cultures. We used the herpes simplex virus-based viral amplicon vector to transduce cortical neurons with three different reporter genes and assessed whether any reporter gene products were toxic over time, by monitoring neurite disintegration and apoptosis. Toxicity varied as a function of the reporter gene, the gene product localization, and the level of reporter gene expression. Transduction of enhanced green fluorescent protein or nuclear-localized β-galactosidase was more toxic than non-nuclear localized β-galactosidase. This work underscores the need for careful design of gene expression constructs. Moreover, in studies where cell injury or toxicity is being evaluated, their use should be carefully considered.
Abstract 540: Role of EphB4-EphrinB2 as novel target in Her2 positive breast cancer.
Authors: A. Duarte, J. Quaresma, A. Trindade, P. Tripathy, X. Liu, V. Krasnoperov, R. Liu, P.S. Gill
Journal: Cancer Research (2013)

Abstract Background: Her2 amplification drives tumor growth in 20% of breast cancers. Her2 targeted therapies have improved survival, but eventual failure occurs and additional targeted therapies to overcome resistance are needed. EphB4 and EphrinB2 receptor kinase -ligand pair is induced in Her2 positive tumors and is a novel target. Methods: Her2 positive tumor cell lines and Her2 transgenic mouse lines were studied for expression of EphB4-EphrinB2. The role of EphB4-EphrinB2 was examined by knock down with shRNA. In vivo tumor xenograft studies with Her2 positive cell lines resistant or sensitive to Her2 targeted therapy, and Her2 transgenic mouse were treated with soluble decoy receptor (soluble EphB4-Albumin fusion protein). Tumor response and activation status of Her2 were examined. Results: EphB4 and EphrinB2 are induced in Her2 positive tumor cell lines with further induction in trastuzumab (Herceptin) resistant tumor lines. Knock down of EphB4 with shRNA reduced the cell viability by nearly 80% compared to control shRNA. In vivo studies with sEphB4-Albumin also reduced the tumor growth by 70-80% accompanied by the reduction in pHer2 and pEGFR. No effect was seen on pHer3. Combination with lapatinib and sEphB4-Albumin was additive. sEphB4-Albumin inhibited tumor growth in Her2 resistant tumor cell lines by 56%. Conclusion: EphB4 and EphrinB2 are induced by Herceptin sensitive and resistant Her2 positive tumors. EphB4 provides survival advantage to Her2 positive trastuzumab sensitive and resistant tumors. sEphB4-Albumin inhibits tumor growth as single agent in both trastuzumab sensitive and resistant tumors. sEphB4-Albumin is currently in the clinical development and thus worthy of investigation in Her2 positive cancers. Citation Format: A. Duarte, J. Quaresma, A. Trindade, P. Tripathy, X. Liu, V. Krasnoperov, R. Liu, P.S. Gill. Role of EphB4-EphrinB2 as novel target in Her2 positive breast cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 540. doi:10.1158/1538-7445.AM2013-540
Treatment of Gram-Negative Bacteremia and Shock with Human Antiserum to a Mutant<i>Escherichia coli</i>
Authors: Elizabeth J. Ziegler, J. Allen McCutchan, Joshua Fierer, Michel P. Glauser, Jerald C. Sadoff, Herndon Douglas, Abraham I. Braude
Journal: New England Journal of Medicine (1982)

In an effort to decrease deaths from gram-negative bacteremia and endotoxin shock, we treated bacteremic patients with human antiserum to endotoxin (lipopolysaccharide) core. Antiserum was prepared by vaccinating healthy men with heat-killed Escherichia coli J5; this mutant lacks lipopolysaccharide oligosaccharide side chains, so that the core, which is nearly identical to that of most other gram-negative bacteria, is exposed for antibody formation. In a randomized controlled trial, patients were given either J5 antiserum or preimmune control serum intravenously, near the onset of illness. The number of deaths in the bacteremic patients was 42 of 109 (39 per cent) in controls and 23 of 103 (22 per cent) in recipients of J5 antiserum (P = 0.011). In those with profound shock, mortality was 30 of 39 (77 per cent) in controls and 18 of 41 (44 per cent) in recipients of J5 antiserum (P = 0.003). We conclude that human antiserum to the lipopolysaccharide core can substantially reduce deaths from gram-negative bacteremia.
Resolving Research Controversies
Authors: Robert Scott
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Resolving Research Controversies Get access Robert Scott Robert Scott Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 17, 4 September 1991, Pages 1213–1214, https://doi.org/10.1093/jnci/83.17.1213 Published: 04 September 1991
Pro-Tobacco Group Attempts to Discredit EPA's Announcement
Authors: F. X. Mahaney
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Pro-Tobacco Group Attempts to Discredit EPA's Announcement Get access Francis X. Mahaney, Jr. Francis X. Mahaney, Jr. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 8, 21 April 1993, Pages 609–610, https://doi.org/10.1093/jnci/85.8.609 Published: 21 April 1993